Experimental treatment strategies in primary cutaneous T-cell lymphomas. Issue 2 (March 2016)

• Record Type: Journal Article
• Authors: Rozati, Sima; Kim, Youn H.
• Is Part Of: Current opinion in oncology. Volume 28:Issue 2(2016:Mar.)
• Publication Date: 2016-03
• Subjects: cancer immunotherapy -- cutaneous T-cell lymphoma -- targeted cancer therapy; Oncology -- Periodicals; 616.994
• DOI: 10.1097/CCO.0000000000000272
• Languages: English
• ISSNs: 1040-8746

Abstract

Abstract : Purpose of review: Cutaneous T-cell lymphoma (CTCL) comprises a heterogeneous group of malignancies derived from skin-homing or resident T cells. Effective treatments are limited, thus new therapies are in development to address the unmet medical need. Recent findings: Recent studies uncovering the genetic alteration in cutaneous T-cell lymphoma have enhanced our understanding of the importance of the T-cell activation/survival pathways, dysregulated immune system, and the relevance of chromatin modification in the pathogenesis of CTCL. New advances in cancer immunomodulation such as with PD1/PD-L1 inhibitors and novel targeted antitumor therapies such as brentuximab vedotin and mogamulizumab as well as potential combination strategies are promising for improving clinical efficacy with manageable toxicity profile. Summary: All these new therapeutic approaches have resulted in broadening the treatment landscape and a potential paradigm shift in the management of CTCL.